The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

V.a

Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

Publications

Lee RE, Lotze MT, Skibber JM, Tucker E, Bonow RO, Ognibene FP, Carrasquillo JA, Shelhamer JH, Parrillo JE, Rosenberg SA

Cardiorespiratory effects of immunotherapy with interleukin-2.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1989;7(1):7-20

Saxon RR, Klein JS, Bar MH, Blanc P, Gamsu G, Webb WR, Aronson FR

Pathogenesis of pulmonary edema during interleukin-2 therapy: correlation of chest radiographic and clinical findings in 54 patients.

AJR. American journal of roentgenology. 1991;156(2):281-5

Vogelzang PJ, Bloom SM, Mier JW, Atkins MB

Chest roentgenographic abnormalities in IL-2 recipients. Incidence and correlation with clinical parameters.

Chest. 1992;101(3):746-52

Morassut S, Balestreri L, Galligioni E, Coran F, Sacco C

[Radiologic characteristics of the thorax during therapy with interleukin-2].

La Radiologia medica. 1992;84(4):368-71